Scarica l'app Stockscreener
6.5194
1.52%
-0.0806
Precedente Chiudi:
$6.60
Aprire:
$7.13
Volume 24 ore:
523.26K
Relative Volume:
0.24
Capitalizzazione di mercato:
$667.11M
Reddito:
-
Utile/perdita netta:
$-29.07M
Rapporto P/E:
-22.48
EPS:
-0.29
Flusso di cassa netto:
$-31.85M
1 W Prestazione:
-7.01%
1M Prestazione:
+20.37%
6M Prestazione:
+123.37%
1 anno Prestazione:
+122.60%
Intervallo 1D:
$6.37
$7.1687
Intervallo di 1 settimana:
$6.37
$7.1687
Portata 52W:
$2.30
$7.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Nome
Trevi Therapeutics Inc
Settore
Industria
Telefono
203-304-2499
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Confronta TRVI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
6.58 | 667.11M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.69 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
539.35 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
545.03 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.12 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
230.82 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-10 | Reiterato | Needham | Buy |
| 2025-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-30 | Iniziato | Raymond James | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-12 | Iniziato | B. Riley Securities | Buy |
| 2022-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | BMO Capital Markets | Outperform |
| 2019-06-03 | Iniziato | Needham | Buy |
| 2019-06-03 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | Stifel | Buy |
Mostra tutto
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Trevi Therapeutics Reports Q1 2025 Results and Updates - TipRanks
MetLife Investment Management LLC Purchases 19,857 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance
Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations - Investing.com
Trevi Therapeutics (TRVI): Promising Data and Strategic Advances | TRVI Stock News - GuruFocus
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings: EPS of -$0.09 Beats Estimate, Reports $10.3 Million Net Loss - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | TRVI Stock News - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
Barclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts - Defense World
Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Invesco Ltd. Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Renaissance Technologies LLC Acquires 29,700 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - Defense World
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 - StreetInsider
Trevi Therapeutics to Report First Quarter 2025 Financial Result - GuruFocus
Trevi Therapeutics Inc [TRVI] Records 50-Day SMA of $5.77 - knoxdaily.com
Indo-Asian News Service - Indo-Asian News Service (IANS)
A look at TRVI’s current quarter earnings estimates - uspostnews.com
TRVI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Quarterly Metrics: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX
SEC Form DEF 14A filed by Trevi Therapeutics Inc. - Quantisnow
JPMorgan Chase & Co. Boosts Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Recent Insider Activity Suggests Potential Gains for Trevi Therapeutics Inc (TRVI) - knoxdaily.com
What is Trevi Therapeutics Inc (TRVI) Stock Return on Shareholders’ Capital? - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Has $5.35 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Quarterly Snapshot: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics Inc (TRVI)’s results reveal risk - uspostnews.com
Stifel maintains Trevi Therapeutics stock Buy rating, $15 target By Investing.com - Investing.com Canada
12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Acquired by Raymond James Financial Inc. - Defense World
American Century Companies Inc. Buys 24,153 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of “Buy” by Analysts - Defense World
Trevi Therapeutics Sees Unusually Large Options Volume (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at Needham & Company LLC - Defense World
Trevi Therapeutics at 24th Annual Needham: Strategic Advances in Cough Treatments - Investing.com Canada
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha
Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
Trevi Therapeutics to Participate in Upcoming April Investor Conferences - The Malaysian Reserve
Trevi's Game-Changing Chronic Cough Treatment Takes Center Stage at 3 Major Healthcare Conferences - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Growth in Short Interest - Defense World
Charles Schwab Investment Management Inc. Has $713,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
What to expect from TRVI’s earnings report this quarter? - uspostnews.com
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones - Proactive financial news
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones | NASDAQ:TRVI - Proactive Investors
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock By Investing.com - Investing.com Australia
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock - Investing.com
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock By Investing.com - Investing.com South Africa
Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Trevi Therapeutics Inc Azioni (TRVI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SCIASCIA THOMAS | Chief Scientific Officer |
Mar 25 '25 |
Sale |
6.60 |
2,631 |
17,365 |
221,373 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Option Exercise |
1.43 |
5,263 |
7,526 |
218,576 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Sale |
6.58 |
5,263 |
34,625 |
213,313 |
2.11%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):